GlassScriptPhysician profile
Gerald James Sprout
NPI 1861916363
$5,325.66
in general payments reported to CMS, 2019-2025
26 companies · $3,681 in 2025
The $3,681 reported for 2025 was more than what 98% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $42.03 · 2023: $628 · 2024: $975 · 2025: $3,681.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,178 · Education: $106.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,177.74 |
| Education | $105.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,168.03 | 2023-2025 | |
| Janssen Biotech, INC. | $590.13 | 2023-2025 | Tremfya, Stelara, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $580.22 | 2022-2025 | Entyvio, Eohilia, Gattex |
| Ardelyx, INC. | $351.70 | 2023-2025 | Ibsrela |
| Genzyme Corporation | $350.86 | 2024-2025 | |
| Madrigal Pharmaceuticals | $314.12 | 2024-2025 | Rezdiffra, Resmetirom |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $285.21 | 2022-2025 | Xifaxan, Relistor, Plenvu |
| Regeneron Healthcare Solutions, INC. | $249.59 | 2024-2025 | Dupixent |
| Aimmune Therapeutics, INC. | $191.81 | 2025 | Zenpep, Vowst |
| Gilead Sciences, INC. | $182.56 | 2024-2025 | |
| Qol Medical, LLC | $180.74 | 2023-2025 | Sucraid |
| Ipsen Biopharmaceuticals, INC | $175.78 | 2024-2025 | Iqirvo, Bylvay |
| Intercept Pharmaceuticals, INC. | $157.91 | 2023-2025 | Ocaliva |
| Lilly USA, LLC | $105.44 | 2024-2025 | Omvoh |
| Merck Sharp & Dohme LLC | $80.11 | 2023-2024 | Dificid, Zinplava |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $67.99 | 2023-2024 | Rebyota |
| Alnylam Pharmaceuticals INC. | $63.06 | 2023-2025 | Givlaari |
| Fresenius Kabi USA, LLC | $47.97 | 2023-2024 | Idacio |
| Mallinckrodt Hospital Products INC. | $45.37 | 2025 | Terlivaz |
| Celltrion USA INC. | $28.90 | 2024 | Zymfentra |
| Mirum Pharmaceuticals, INC. | $24.72 | 2025 | Livmarli |
| Biocon Biologics INC | $20.15 | 2025 | Yesintek |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.49 | 2023 | Cyltezo |
| Evoke Pharma, INC. | $17.25 | 2025 | |
| Phathom Pharmaceuticals, INC. | $15.07 | 2024 | Voquezna |
| Pfizer INC. | $13.48 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gerald Sprout listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.